Contributions
Abstract: EP493
Type: E-Poster Presentation
Session title: Acute myeloid leukemia - Clinical
Background
In previous study, we found that peripheral blood blast percentages on day 7 (D7PBBP) of induction chemotherapy significantly associated with remission and long-term outcomes of patients with acute myeloid leukemia (AML). Moreover, D7PBB7 was proven to be an independent indicator for unfavorable prognosis.
Aims
The aim of this study was to assess the prognostic significance of D7PBBP for AML patients with a larger patient sample.
Methods
A retrospective analysis was performed with 137 AML (excluding those with acute promyelocytic leukemia) patients enrolled in this study between October 1, 2015 to October 31, 2018. D7PBBP was determined by flow cytometry. The previous patient cohort in our published study was used as training set, and patients of the present study were regarded as validation set.
Results
Of the 137 patients received one course of standard induction chemotherapy, 100 cases (73.0%) achieved complete remission (CR). With the cut-off value of 0.945% used in training set, the significant association between D7PBBP and achieving CR after one course of chemotherapy also could be observed in validation set (CR rates of patients with D7PBBP ≥0.945% vs. <0.945% were 38.2% vs. 84.5%; P < 0.001). Furthermore, D7PBBP was significantly related with levels of minimal residual disease (MRD) in the bone marrow (negative MRD rates were 17.7% and 40.8% in patients with D7PBBP ≥0.945% and <0.945%, respectively; P = 0.014). Similar to our training set, the cutoff value of 0.43% could be used to re-stratify prognosis of patients with AML. Patients with low D7PBBP (<0.43%) had significantly superior relapse-free survival (RFS) and overall survival (OS) compared with those with high levels of D7PBBP (≥0.43%). Additionally, we found that D7PBBP was potential marker for prognostic re-stratification in AML patients with low and intermediate cytogenetic karyotypes.
Conclusion
In summary, these results indicated that D7PBBP could predict treatment responses and long-term outcomes for patients with AML. Furthermore, D7PBBP was potential index to be integrated into cytogenetics-based risk adapted prognostic system for AML patients in low and intermediate risk group.
Keyword(s):
Abstract: EP493
Type: E-Poster Presentation
Session title: Acute myeloid leukemia - Clinical
Background
In previous study, we found that peripheral blood blast percentages on day 7 (D7PBBP) of induction chemotherapy significantly associated with remission and long-term outcomes of patients with acute myeloid leukemia (AML). Moreover, D7PBB7 was proven to be an independent indicator for unfavorable prognosis.
Aims
The aim of this study was to assess the prognostic significance of D7PBBP for AML patients with a larger patient sample.
Methods
A retrospective analysis was performed with 137 AML (excluding those with acute promyelocytic leukemia) patients enrolled in this study between October 1, 2015 to October 31, 2018. D7PBBP was determined by flow cytometry. The previous patient cohort in our published study was used as training set, and patients of the present study were regarded as validation set.
Results
Of the 137 patients received one course of standard induction chemotherapy, 100 cases (73.0%) achieved complete remission (CR). With the cut-off value of 0.945% used in training set, the significant association between D7PBBP and achieving CR after one course of chemotherapy also could be observed in validation set (CR rates of patients with D7PBBP ≥0.945% vs. <0.945% were 38.2% vs. 84.5%; P < 0.001). Furthermore, D7PBBP was significantly related with levels of minimal residual disease (MRD) in the bone marrow (negative MRD rates were 17.7% and 40.8% in patients with D7PBBP ≥0.945% and <0.945%, respectively; P = 0.014). Similar to our training set, the cutoff value of 0.43% could be used to re-stratify prognosis of patients with AML. Patients with low D7PBBP (<0.43%) had significantly superior relapse-free survival (RFS) and overall survival (OS) compared with those with high levels of D7PBBP (≥0.43%). Additionally, we found that D7PBBP was potential marker for prognostic re-stratification in AML patients with low and intermediate cytogenetic karyotypes.
Conclusion
In summary, these results indicated that D7PBBP could predict treatment responses and long-term outcomes for patients with AML. Furthermore, D7PBBP was potential index to be integrated into cytogenetics-based risk adapted prognostic system for AML patients in low and intermediate risk group.
Keyword(s):